Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Alvarez, Sviderskiyet al. have identified a pathway that allows primary lung tumour cells or lung metastatic breast tumour cells to survive in the high oxygen concentrations present in the lung.
Ubiquitin ligases (E3s) participate in many cellular processes, including cell cycle progression and cell death. This Review by Senftet al. discusses how deregulation of E3s can lead to tumorigenesis and highlights the opportunities for targeting E3s as an anticancer therapy.
Inactivating mutations in the tumour suppressor geneTP53are frequent in cancer. This Review provides a critical overview of reactivating p53 as a therapeutic strategy, describing preclinical and clinical compounds that re-establish the functions of wild-type p53 in tumours.
Field cancerization underlies the development of many types of cancer. This Review examines the biological mechanisms that drive the evolution of cancerized fields and discusses how measuring field evolution could improve cancer risk prediction in patients with pre-malignant disease.
The importance of 'Warburgian' metabolism in cancer is an increasingly disputed topic. By studying cancer metabolism in patients and mouse models, Faubertet al. now show that lactate is used as a respiratory fuel in non-small-cell lung cancer in vivo.
New research published inNaturenow demonstrates that immune checkpoint blockade can alleviate hepatocellular carcinoma progression in patients with nonalcoholic steatohepatitis (NASH) by inhibiting immunosuppressive immunoglobulin A-producing cells in the liver.
Melloet al. analysed the effects of various p53 transactivation domain mutants in pancreatic ductal adenocarcinoma and uncovered a crucial tumour-suppressive pathway in which p53 mediates inhibition of the transcriptional co-activator YAP.
A modular synthetic RNA-based gene circuit has been developed to program tumour cells to express a combination of immunomodulators to improve the specificity and efficacy of cancer immunotherapy.
Sympathetic nerves associate with tumours and regulate the tumour microenvironment. How this innervation promotes tumorigenesis is unclear. A new study in Scienceshows that β-adrenergic signalling controls tumour growth by promoting tumour angiogenesis, through the regulation of vascular metabolism.
Differentiation therapy has shown great success in the treatment of acute promyelocytic leukaemia (APL). This Opinion article discusses the molecular basis for the success of APL treatment and the potential of drug-induced tumour cell differentiation in other malignancies.
Small-cell lung cancer is an aggressive form of lung cancer and has been difficult to treat due to therapy resistance. This Review discusses challenges and recent advances in uncovering molecular changes that allow potentially efficient therapies.
This Review by Dewhirst and Secomb describes the current understanding of drug transport to tumour cells and the progress that has been made in developing methods to enhance drug delivery.
